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Abstract
b-site APP cleaving enzyme 1 (BACE1) is a transmembrane aspartyl protease with a lumenal active site that sheds the
ectodomains of membrane proteins through juxtamembrane proteolysis. BACE1 has been studied principally for its role in
Alzheimer’s disease as the b-secretase responsible for generating the amyloid-b protein. Emerging evidence from mouse
models has identified the importance of BACE1 in myelination and cognitive performance. However, the substrates that
BACE1 processes to regulate these functions are unknown, and to date only a few b-secretase substrates have been
identified through candidate-based studies. Using an unbiased approach to substrate identification, we performed
quantitative proteomic analysis of two human epithelial cell lines stably expressing BACE1 and identified 68 putative b-
secretase substrates, a number of which we validated in a cell culture system. The vast majority were of type I
transmembrane topology, although one was type II and three were GPI-linked proteins. Intriguingly, a preponderance of
these proteins are involved in contact-dependent intercellular communication or serve as receptors and have recognized
roles in the nervous system and other organs. No consistent sequence motif predicting BACE1 cleavage was identified in
substrates versus non-substrates. These findings expand our understanding of the proteins and cellular processes that
BACE1 may regulate, and suggest possible mechanisms of toxicity arising from chronic BACE1 inhibition.
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Introduction
Alzheimer’s disease is the most common neurodegenerative
disorder, affecting more than 5 million Americans and over 30
million people worldwide. In the US alone, the disease accounts for
an estimated $148 billion dollars annually in healthcare expenses
[1]. Despite the growing understanding of the molecular processes
that lead to this disease, there is as yet no disease-modifying
treatment. Accumulation and deposition of the amyloid-b (Ab)
protein is thought to be a precipitating factor driving disease
pathogenesis [2]. Ab is known to be a toxic stimulus in a variety of
model systems, and emerging experimental and clinical attempts to
intervene in the disease process have shown preliminary success by
preventingtheproduction orenhancing clearanceofthe Ab peptide
[3,4,5,6].
Ab is produced from two proteolytic cleavages of the amyloid
precursor protein (APP). The first of these is performed by b-secretase
onthelumenaldomainofAPP,secretingtheAPPectodomain(APPs)
into the extracellular space. The second cleavage is executed by the
intramembrane protease, c-secretase, within the hydrophobic lipid
bilayer. These sequential biochemical events are essential for Ab
formation, and thus these two proteases have become principal
targets for pharmacological intervention in Alzheimer’s disease.
b-site APP cleaving enzyme 1 (BACE1), or memapsin-2, is an
aspartic protease of the pepsin family that was identified as the
principal b-secretase responsible for Ab generation nearly a
decade ago [7,8,9,10,11,12]. BACE1 is necessary for Ab pro-
duction in vivo [13], and genetic BACE1 deficiency rescues amyloid
pathology and deficits seen in APP transgenic mice [14].
Currently, BACE1 inhibitors are in development for the treatment
of Alzheimer’s disease [15]. Our understanding of the normal
biological functions of BACE1 is far from complete, as the
majority of efforts to study this protease have focused solely on its
role in Ab generation. BACE1 is thought to have loose substrate
specificity, with preferences including a leucine residue at P1 and a
polar residue at P1’ positions [16,17,18]. However, the few known
BACE1 substrates do not strictly adhere to cleavage recognition
motifs emerging from these in vitro studies.
BACE1 is primarily expressed within the central nervous system
and predominantly by neurons [8]. Because few substrates of
BACE1 have been identified and BACE1 knockout mice were
initially described as having no phenotype, chronic inhibition of
BACE1 has been proposed as a potentially attractive therapy
for Alzheimer’s disease. However, several recent studies have
highlighted myelination, behavioral and synaptic abnormalities
in BACE1 knockout mice, suggesting that this protease plays
important functions in the development and maintenance of the
nervous system [19,20,21]. Which substrates BACE1 processes to
regulate these complex phenotypes is unknown. These results
highlight the limitations in our understanding of the normal
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adverse effects BACE1 inhibition may produce in humans.
In order to better understand the normal cellular functions of
BACE1, we have utilized quantitative proteomic methods in a cell
culture model to identify the range of proteins that are regulated by
b-secretase processing. Using this approach, we have discovered a
largenumberofnovelproteinssubjecttob-secretasecleavageintwo
human epithelial cell lines. Interestingly, many of these proteins are
involved in contact-dependent intercellular communication or serve
as receptors and have recognized roles in the nervous system and
other tissues. The vast majority of these proteins are of type I
transmembrane topology, with one having type II topology and
three having glycophosphatidylinositol (GPI) anchors. Our findings
indicate that BACE1 has a strong preference for single-pass
membrane bound proteins, but that the transmembrane and
cytoplasmic domains do not play obligate roles in recognition by b-
secretase. We validated a subset of the identifiedsubstrates and non-
substrates in a cell culture model, either through analysis of the
endogenous protein or by stably expressing the candidate. Analysis
of the primary sequence of the BACE1 substrates suggests several
potential sites of cleavage. However, as non-substrates also bear
potentialb-secretasecleavagesites,primarysequenceappearsnotto
be the principal determinant of substrate selection. Our results
demonstratethe broad role of BACE1 activity in membrane protein
turnover, and suggest that this protease may help regulate many
diverse biological processes.
Results
Quantitative Proteomics of Conditioned Medium from
Cells Expressing BACE1 Identifies Many Novel b-Secretase
Substrates
Stable isotope labeling with amino acids in cell culture (SILAC),
in which cells of different genetic backgrounds or experimental
conditions are differentially grown in the presence of heavy or light
amino acids, enables sensitive and quantitative comparisons
between two proteomes using mass spectrometry. Previously, we
used this experimental approach to identify novel substrates of the
intramembrane aspartyl protease c-secretase [22]. In the present
study, we use similar proteomic methods, coupled with genetic
overexpression of BACE1, to identify in an unbiased fashion the
proteins regulated by b-secretase in two epithelial cell lines.
The human cell lines used in this study were HEK and HeLa,
derived from transformed embryonic kidney cells and cervical
adenocarcinoma, respectively. HEK cells and, to a lesser extent
HeLa cells, express a very low level of BACE1 protein, as
evidenced by their modest capacity to produce Ab. BACE1 is
principally expressed within the nervous system [8], and
endogenous BACE1 protein is undetectable by Western blot in
these cell lines (see below). For these reasons, we chose to use a
BACE1 overexpression system to enhance b-secretase activity and
achieve levels of substrate shedding sufficient for proteomic
identification. HEK and HeLa cell lines were each stably
transfected with either myc tagged human BACE1 cDNA or an
empty vector as control. HEK cells achieved higher BACE1
expression than HeLa cells (Figure 1A–B, top panels).
As an initial validation of this system for monitoring b-secretase
activity, endogenous levels of the prototypical BACE1 substrate,
APP, were analyzed (Figure 1). The metalloprotease (a-secretase)
inhibitor GM6001, the b-secretase inhibitor C3 and the c-secretase
inhibitor DAPT were used to characterize the three principal
proteolytic events in APP processing. Expression of BACE1 led to a
clear decrease in the amount of mature APP in both HEK and
HeLa cells, but the levels of immature, incompletely glycosylated
APP remained unchanged (Figure 1A–B, middle panels). BACE1
shedding of mature APP was reversible upon application of a
b-secretase inhibitor (C3). This finding indicates proper localization
of b-secretase activity to post-Golgi compartments, where the
enzyme typically resides on the cell surface and within the
endosomal system [23]. APP C-terminal fragments (CTFs) are
produced after ectodomain shedding by either a-o rb-secretase
enzymes. Normally, CTFs are rapidly turned over via intramem-
brane proteolysis by the c-secretase complex, liberating an
intracellular domain and a small secreted Ab-like peptide. Upon
c-secretase inhibition with DAPT, CTFs accumulate to detectable
levels, and CTF levels were further enhanced by the increased
ectodomain shedding produced by BACE1 overexpression
(Figure 1A–B, lower panels).
Using an ectodomain directed APP antibody, we analyzed the
cellular conditioned medium for changes in secreted APP (APPs)
arising from BACE1 expression (Figure 1C–D; quantification
shown in Figure 1E). Under control conditions, APPs levels
decrease by approximately 50% in response to metalloprotease (a-
secretase) inhibition, and by approximately 30% in response to b-
secretase inhibition. With BACE1 expression, APPs levels increase
4- to 5-fold above control, and this effect is entirely reversed by b-
secretase inhibition with C3, confirming the specificity of our
paradigm. Two distinct bands correspond to APPs, and both result
from a- and b-secretase processing, as indicated by the inhibitor
and overexpression experiments (Figure 1). Further, in the case of
BACE1 expression, both bands arise from cleavage of the mature
form of APP. Although the explanation for two distinct APPs
species is unclear, they may arise from either different protein
conformations that alter electrophoretic migration, or alternatively
the occurrence of post-cleavage modification of APPs such as
ectodomain phosphorylation [24,25].
With these results validating the effects of BACE1 overexpres-
sion on one endogenous substrate, we next sought to probe the
entire proteome of these two cell lines for proteins whose shedding
was increased by elevated b-secretase activity. Stable BACE1 cells
were metabolically labeled with heavy lysine and arginine, whereas
control cells were labeled with the light form of these amino acids
(see Materials and Methods for details). Once labeled and grown
to confluence, cells were conditioned in serum-free medium
containing 20 mM GM6001. This metalloprotease inhibitor was
added to the conditioning medium of both BACE1 and control
cells for two reasons. First, several of the known b-secretase
substrates are subject to both metalloprotease (a-secretase) and b-
secretase processing. As seen with APP (Figure 1E), addition of
GM6001 enhances the difference in APPs levels between BACE1
and control conditions 2-fold. This enhanced difference in the
abundance of BACE1-cleaved products was anticipated to
increase our ability to detect potential substrates. Second, by
decreasing basal metalloprotease shedding of proteins, particularly
by the a disintegrin and metalloprotease (ADAM) and the matrix
metalloprotease (MMP) family of enzymes, the complexity of the
resultant conditioned medium may be reduced and thus improve
our ability to detect low-abundance peptides.
Conditioned medium was collected from the BACE1 and
control cells grown to equal confluence, and the medium
combined in parallel for HEK and HeLa cells. This combined
medium was then concentrated approximately 200-fold through a
centrifugal filter device with a 3 kDa molecular weight cutoff. One
hundred micrograms of protein from the concentrated condi-
tioned medium was separated by SDS-PAGE, divided into ten
horizontal slices, and subject to trypsinization and LC-MS/MS
(see Figure S1 and Materials and Methods). Data arising from all
quantitative peptide comparisons were analyzed to enrich for
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with BACE1 expression. Proteins were considered as putative
substrates when constituent peptides were found with at least 65%
of the total (light plus heavy) signal derived from the BACE1
(heavy) condition. One hundred and sixteen proteins were
identified that showed this degree of enrichment in the BACE1
conditioned medium, and these individual candidates were further
evaluated.
Based on the known functions of BACE1 and the short list of
established b-secretase substrates, we expected to find solely
membrane-bound proteins enriched in the medium of BACE1
expressing cells. However, many of the proteins enriched in the
BACE1 condition were not membrane-bound and are unlikely to
be direct substrates of b-secretase. These are unlikely to be
contaminants from lysed cells, as such an artifact should be present
in equal abundance between the two conditions. An example of
how such proteins may become enriched in the medium of
BACE1 overexpressing cells is the co-secretion of a non-
membrane-bound protein associated with another membrane
protein that is itself cleaved by b-secretase. Alternatively,
mistrafficking of a protein may occur after b-secretase cleavage
of a receptor responsible for determining its localization.
Unexpectedly, 43 of the 116 proteins elevated by BACE1
expression were soluble, non-membrane bound lysosomal proteins
(Table S2). Investigation of the putative b-secretase substrates
revealed the shedding of a membrane protein responsible for
Figure 1. Characterization of cell lines expressing BACE1. HEK (left column) and HeLa (right column) cell lines were generated that stably
express either BACE1 or an empty vector as control. To monitor changes in APP processing cells were treated with the metalloprotease (a-secretase)
inhibitor GM6001, the b-secretase inhibitor C3 and the c-secretase inhibitor DAPT. (A–B) Cell lysates were probed for the presence of myc-tagged
BACE1 (top panel); endogenous full-length APP, which is present in a mature, fully glycosylated form (mAPP) and an incompletely glycosylated
immature form (iAPP, middle panel); and membrane-bound APP CTFs (bottom panel) produced by ectodomain shedding. (C–D) Abundance of APPs
in conditioned medium of the various treatment conditions. (E) Quantification of secreted APPs levels arising from the different treatments. Data from
both cell lines were combined, and normalized to the control (DMSO) condition. The fold-accumulation of APPs arising from the various treatment
conditions vs. DMSO control is graphed; * p , 0.05. ‘‘+’’ indicates the addition of a drug while ‘‘2’’ indicates the addition of DMSO as a control. The
molecular weight in kDa is shown to the left of each Western blot panel.
doi:10.1371/journal.pone.0008477.g001
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secreted lysosomal proteins were likely elevated in BACE1
conditioned medium due to the shedding of a receptor responsible
for their trafficking (see below for further details). Peptides derived
from BACE1 were found to be elevated in the media of cells
expressing the protease, although we determined that BACE1
cannot shed itself (see below). Only four other non-membrane
bound proteins were found to be elevated in the media of BACE1
expressing cells, and of these, three were related to collagen
synthesis and one was a secreted protease inhibitor (Table S2).
Of the 116 proteins elevated in the conditioned medium of
BACE1 expressing cells, 68 were integral membrane proteins
whose presence in the medium indicates their shedding (Table 1,
additional information in Table S1). Analyzed by cell line, 47
putative substrates were found unique to HEK cells, five unique to
HeLa cells, and 16 shared between the two cell lines (Figure 2A).
All of these proteins were found to be either single-pass integral
membrane proteins or GPI-linked proteins. The vast majority, 64
of 68, were type I transmembrane proteins. The four remaining
putative substrates include three GPI-linked and one type II
transmembrane protein (Figure 2B). Based on descriptions of
protein function in the Gene Ontology and UniProt databases,
these 68 substrates were divided into functional categories
(Figure 2C). Many of the putative substrates are involved in
contact-dependent intercellular communication by interacting
with a membrane-bound cognate ligand on another cell. Members
of this group include proteins implicated in neurodevelopment and
migration, immune function, and cell fate determination. Other
putative substrates have been described to function as peptide and
lipoprotein receptors, cellular adhesion molecules, proteases, and
in intracellular protein trafficking.
Asonewouldexpectforaproteinshed byb-secretase,allpeptides
that we identified should liewithin the ectodomainof the protein, or
possibly within an Ab-like peptide if the remaining membrane-
bound fragment undergoes intramembrane proteolysis. As an
example of how these peptides map onto a protein, peptides
derived from APP are illustrated in Figure 2D. As expected, all
peptides lie within the ectodomain and are N-terminal to the known
b-secretase cleavage sites. We mapped the majority of peptides
identified by mass spectrometry to the full-length sequences of the
putative b-secretase substrates, and as expected, all peptides
correspond to the ectodomain region (Figure S2). The only
exception was a peptide from the protein sidekick-2 that includes
the entire transmembrane domain. Previously, twelve proteins have
beenimplicatedas b-secretasesubstrates [22,26,27,28,29,30,31,32],
and we were able to identify five of these (APP, APLP1, APLP2,
LRP and DSG2) through our unbiased proteomic methods. The
remaining 63 proteins we discovered are thus novel putative
BACE1 substrates.
Shedding of GPI-Linked and Type II Membrane Proteins
by b-Secretase
To improve our confidence in the list of novel b-secretase
substrates shown in Table 1, we sought to validate the BACE1-
dependent shedding of several of the most interesting candidates.
We used two methods in approaching the validation of these
candidates: 1) probe with an antibody against the endogenous
protein when available, or 2) clone, epitope tag and stably express
the gene encoding the protein of interest. All validation
experiments were performed in HEK cells that stably overexpress
BACE1 or an empty vector as control.
Of the 68 proteins implicated as b-secretase substrates by
proteomic identification, only four were non-type I transmem-
brane proteins. Three GPI-linked proteins, which undergo post-
translational processing at the C-terminus that replaces a
hydrophobic sequence with a glycophosphatidylinositol anchor,
were identified as putative b-secretase substrates. To validate the
b-secretase processing of a GPI-anchored protein, we examined
ephrin-A5. Ephrins are cell-surface signaling molecules that bind
in trans to Eph receptor tyrosine kinases to mediate intercellular
communication. They have been studied largely in the context of
neurodevelopment, in which they function to promote migration,
attraction, repulsion and adhesion of cells and growth cones [33].
Ephrin-A5, in addition to signaling forward through its Eph
cognate ligand, facilitates reverse signaling by forming compart-
mentalized microdomains [34]. Ephrins have previously been
shown to undergo ADAM-dependent cleavage, which is thought
to break the adhesive intercellular contact between Eph and
ephrins to promote cellular detachment and repulsion [35].
Ephrin-A5 was N-terminally FLAG tagged and stably expressed
in HEK cells. Cellular lysates demonstrate robust expression of the
full-length protein (Figure 3A, left panel). b-secretase activity
decreased the level of the full-length protein, and produced a lower
molecular weight band consistent with some shed ectodomain
retained within the cell. Conditioned medium from ephrin-A5
expressing cells revealed the presence of a major shed band
dependent on b-secretase activity (Figure 3A, right panel),
establishing ephrin-A5 as a BACE1 substrate. In addition, a weak
band of slightly higher molecular weight was observed and likely
corresponds to the a-secretase (metalloprotease) shed ectodomain
[35].
Golgi integral membrane protein 4 (GOLIM4), the sole type II
transmembrane protein identified, has been shown to cycle
between the Golgi apparatus and endosomes, where it functions
in a bypass trafficking pathway that removes proteins from
recycling endosomes to the Golgi [36]. In addition, GOLIM4
bypass trafficking is appropriated by Shiga toxin to facilitate toxin
entry into the Golgi [37]. HEK cell lines stably expressing
GOLIM4 produced only weak amounts of full-length protein, as
shown by Western blotting (Figure 3B, left panel). The conditioned
medium from these cells, however, showed robust accumulation of
the shed GOLIM4 ectodomain that depended upon b-secretase
activity (Figure 3B, right panel). These data demonstrate that
BACE1 is capable of shedding some type II and GPI-linked
proteins.
Type I Transmembrane Proteins Are the Predominant
Substrates of b-Secretase
As previous research identified BACE1 substrates only through
candidate-based approaches, it has remained unclear whether the
enzyme exhibits any preference for substrate topology. The large
majority of the putative substrates we identified, numbering 64,
were type I transmembrane proteins. These results suggest a
strong intrinsic bias of b-secretase towards type I proteins, which
may reveal some insight into how the enzyme recognizes its
substrates. In addition to confirming the b-secretase processing of
several type I transmembrane proteins identified as putative
substrates, we also sought to scrutinize several candidate non-
substrate proteins to observe if their abundance or processing
changes in response to BACE1 expression.
The leucine-rich repeats and immunoglobulin-like domains
(LRIG) family is constituted by three type I integral membrane
proteins that are broadly expressed in many tissues. The LRIG
family has been found to antagonize growth factor signaling [38],
and alterations in the expression of LRIG proteins is thought to
play a role in tumorigenesis [39]. It has been demonstrated
recently that a recombinant soluble ectodomain of LRIG1
antagonizes epidermal growth factor receptor signaling [40],
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Gene Protein Topology Cell Line PSMs Unique PSMs Ratio
APP AMYLOID BETA A4 PROTEIN Type I HEK HeLa 169 8 0.89
APLP1 AMYLOID-LIKE PROTEIN 1 Type I HEK HeLa 10 4 0.89
APLP2 AMYLOID-LIKE PROTEIN 2 Type I HEK HeLa 165 9 0.96
IGF2R CATION-INDEPENDENT MANNOSE-6-PHOSPHATE RECEPTOR Type I HEK HeLa 135 4 0.88
IL6ST INTERLEUKIN-6 RECEPTOR BETA CHAIN Type I HEK HeLa 8 3 0.98
MET HEPATOCYTE GROWTH FACTOR RECEPTOR Type I HEK HeLa 13 3 0.74
CPD CARBOXYPEPTIDASE D Type I HEK 91 3 0.87
EPHA2 EPHRIN TYPE-A RECEPTOR 2 Type I HEK 2 1 0.94
EPHA4 EPHRIN TYPE-A RECEPTOR 4 Type I HEK 5 1 0.93
EPHA7 EPHRIN TYPE-A RECEPTOR 7 Type I HEK 10 2 0.93
EPHB4 RECEPTOR PROTEIN TYROSINE KINASE VARIANT EPHB4V1 Type I HEK HeLa 7 3 0.95
NCAM1 NEURONAL CELL ADHESION MOLECULE 1 Type I HEK 11 4 0.88
L1CAM NEURAL CELL ADHESION MOLECULE L1 Type I HeLa 7 2 0.78
SEMA4B SEMAPHORIN-4B Type I HEK HeLa 7 2 0.79
SEMA4C SEMAPHORIN-4C Type I HEK 8 2 0.92
SEMA6A SEMAPHORIN-6A Type I HEK 1 1 0.70
SEMA6D SEMAPHORIN-6D Type I HEK 1 1 0.92
LRIG1 LEUCINE-RICH REPEATS AND IMMUNOGLOBULIN-LIKE DOMAINS PROTEIN 1 Type I HEK 2 2 0.85
LRIG2 LEUCINE-RICH REPEATS AND IMMUNOGLOBULIN-LIKE DOMAINS PROTEIN 2 Type I HEK 1 1 0.92
LRIG3 LEUCINE-RICH REPEATS AND IMMUNOGLOBULIN-LIKE DOMAINS PROTEIN 3 Type I HEK 2 2 0.89
ROBO1 ROUNDABOUT HOMOLOG 1 Type I HEK HeLa 27 3 0.81
ROBO2 ROUNDABOUT HOMOLOG 2 Type I HEK 1 1 1.00
SDK1 SIDEKICK-1 Type I HEK 14 1 0.88
SDK2 SIDEKICK-2 Type I HeLa 8 2 0.91
PVR POLIOVIRUS RECEPTOR Type I HEK HeLa 11 3 0.73
SORL1 SORTILIN-RELATED RECEPTOR Type I HEK 2 1 0.71
SORT1 SORTILIN Type I HEK 8 1 0.84
PCDH21 PROTOCADHERIN 21 Type I HEK 10 2 0.76
PCDH7 PROTOCADHERIN 7 Type I HEK 14 2 0.89
PCDHGA11 PROTOCADHERIN GAMMA A11 Type I HEK 2 1 0.90
PCDHGA5 PROTOCADHERIN GAMMA A5 Type I HEK 1 1 0.99
PCDHGA8 PROTOCADHERIN GAMMA A8 Type I HEK 1 1 0.95
PCDHGC3 PROTOCADHERIN GAMMA C3 Type I HEK 1 1 0.83
CD276 CD276 ANTIGEN Type I HEK 3 2 0.70
LRP11 LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 11 Type I HEK HeLa 9 3 0.91
LRP4 LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 4 Type I HEK 7 1 0.89
PAM PEPTIDYL-GLYCINE ALPHA-AMIDATING MONOOXYGENASE Type I HEK 19 3 0.74
PODXL PODOCALYXIN-LIKE PROTEIN 1 Type I HEK 2 2 0.95
SDC4 SYNDECAN-4 Type I HEK 10 4 0.96
BACE1 BETA-SECRETASE 1 Type I HEK 10 4 0.90
HLA HLA CLASS I HISTOCOMPATIBILITY ANTIGEN (Combined) Type I HEK HeLa 15 12 0.92
PLXDC2 PLEXIN DOMAIN-CONTAINING PROTEIN 2 Type I HEK HeLa 10 3 0.81
BSG BASIGIN Type I HEK HeLa 3 3 0.81
PTPRS RECEPTOR-TYPE TYROSINE-PROTEIN PHOSPHATASE S Type I HEK 2 2 0.88
ALCAM CD166 ANTIGEN Type I HEK HeLa 2 2 0.92
LMAN2 VESICULAR INTEGRAL-MEMBRANE PROTEIN VIP36 Type I HEK 2 1 0.75
CACHD1 CACHE DOMAIN CONTAINING 1 Type I HEK 45 1 0.84
SEZ6L2 SEIZURE 6-LIKE PROTEIN 2 Type I HEK 19 1 0.92
NEO1 NEOGENIN Type I HEK 10 1 0.75
PRTG PROTOGENIN Type I HEK 9 1 0.97
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has not previously been described. By mass spectrometry, we
identified one unique peptide each of LRIG1 and LRIG3, and one
peptide conserved in sequence between the three LRIG family
members, each of which was elevated in conditioned media by b-
secretase activity (Table 1). To validate that the LRIG family is
indeed subject to b-secretase processing, we stably expressed N-
terminally FLAG tagged LRIG2 and LRIG3 in HEK cells also
stably expressing either BACE1 or an empty vector as control.
Lysates of the LRIG2 and LRIG3 expressing cells modestly
produced the full-length protein (Figure 4A–B, left panels), with
LRIG2 being present in multiple bands likely arising from
differential glycosylation. In the conditioned medium of LRIG2
and LRIG3 expressing cells, BACE1 expression produced
an immunoreactive band indicative of ectodomain shedding
(Figure 4A–B, right panels), and whose presence was sensitive to
a b-secretase inhibitor. These results verify that BACE1 can cleave
the LRIG family of proteins.
Insulin-like growth factor 2 receptor (IGF2R), also known as
cation-independent mannose-6-phosphate receptor (M6PR), is a
multifunctional glycoprotein. It serves as a receptor for IGF2,
TGF-b, LIF, retinoic acid and other ligands [41]. Unlike the
IGF1R, which signals upon ligand binding as a receptor tyrosine
kinase, IGF2R has a smaller cytoplasmic domain with several
potential phosphorylation sites but an incompletely characterized
signaling function. The IGF2R has been proposed to function
simply by binding and degrading ligands, but emerging evidence
demonstrates that IGF2R is capable of signal transduction and
that ligand binding modifies cellular behavior [42,43]. Another
well-defined role for this receptor is to bind newly synthesized
soluble lysosomal proteins bearing mannose-6-phosphate, promote
aggregation and internalization into clathrin-coated vesicles, and
transport the bound lysosomal proteins to late endosomes for
activation. The IGF2R protein is then recycled to the secretory
pathway or the cell surface [44]. The existence of IGF2R shedding
has been suggested by previous studies which have found soluble
IGF2R in human serum, amniotic fluid and urine. By sequestering
soluble growth factor ligands, the shed product may act as a
negative regulator of growth [45].
We examined endogenously expressed IGF2R in HEK cells
using an ectodomain directed antibody. In cell lysates, we detected
the large IGF2R protein and found, like other BACE1 substrates,
that the levels of full-length protein decrease with b-secretase
activity (Figure 4C, left panel). In conditioned medium, shedding
of the endogenously expressed IGF2R ectodomain was detectable
under control conditions and was increased several fold with b-
secretase activity (Figure 4C, right panel), thus validating IGF2R
as a BACE1 substrate. The identification of IGF2R/M6PR as a
substrate of b-secretase also provides a clear mechanistic
explanation for the presence of soluble lysosomal enzymes in the
conditioned medium of BACE1 expressing cells (see Discussion for
further details).
We next examined b-secretase processing of endogenous
amyloid precursor-like protein-1 (APLP1). Although APLP1 has
already been identified as a BACE1 target [26,46], its validation
was of interest because APLP1 is expressed primarily in the central
nervous system [47], and its shed ectodomain was unexpectedly
identified here by mass spectrometry in the epithelial HEK and
HeLa cell lines (Table 1). Using an ectodomain-specific antibody,
we were unable to detect full-length APLP1 in cellular lysates
(Figure 4D, left panel), consistent with low or nearly absent
expression of this protein in epithelial cells. However, examination
Gene Protein Topology Cell Line PSMs Unique PSMs Ratio
UNC5C NETRIN RECEPTOR UNC5C Type I HEK 8 1 0.92
ITFG1 T-CELL IMMUNOMODULATORY PROTEIN Type I HEK 5 1 0.97
CSPG4 CHONDROITIN SULFATE PROTEOGLYCAN 4 Type I HEK 4 1 0.68
TMEM132A TRANSMEMBRANE PROTEIN 132A Type I HEK 3 1 0.72
ADAM10 DISINTEGRIN AND METALLOPROTEINASE DOMAIN-CONTAINING PROTEIN 10 Type I HEK 2 1 0.68
BAMBI BMP AND ACTIVIN MEMBRANE-BOUND INHIBITOR HOMOLOG Type I HEK 2 1 0.98
SPINT2 KUNITZ-TYPE PROTEASE INHIBITOR 2 Type I HEK 2 1 0.96
DSG2 DESMOGLEIN 2 Type I HEK 1 1 0.95
CRIM1 CYSTEINE-RICH MOTOR NEURON 1 PROTEIN Type I HEK 1 1 0.90
GLG1 GOLGI APPARATUS PROTEIN 1 Type I HeLa 1 1 0.89
JAG1 JAGGED-1 Type I HEK 1 1 0.97
LRRC33 LEUCINE-RICH REPEAT-CONTAINING PROTEIN 33 Type I HeLa 1 1 1.00
TGOLN2 TRANS-GOLGI NETWORK INTEGRAL MEMBRANE PROTEIN 2 Type I HEK 1 1 0.90
TLR9 TOLL-LIKE RECEPTOR 9 Type I HeLa 1 1 0.66
TNFRSF21 TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 21 Type I HEK 1 1 1.00
CNTN1 CONTACTIN-1 GPI HEK 4 2 0.87
EFNA5 EPHRIN-A5 GPI HEK HeLa 2 2 0.71
GPC3 GLYPICAN-3 GPI HEK 2 2 0.75
GOLIM4 GOLGI PHOSPHOPROTEIN 4 Type II HEK 5 2 0.92
Columns indicate the gene and protein names, membrane topology, the cell line in which the protein was identified, the number of peptide spectral matches (PSMs) for
the indicated protein, unique PSMs (indicating how many unique peptides were identified), and the average ratio of BACE1 peptides to total peptides identified. Data
are sorted according to protein families.
doi:10.1371/journal.pone.0008477.t001
Table 1. Cont.
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PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8477Figure 2. Regulation of single-pass and GPI-linked proteins by BACE1. Putative substrates identified to undergo BACE1 shedding in HEK
and HeLa cells were examined for topology and proposed function. (A) Venn diagram indicating the total number of putative BACE1 substrates
identified, and the number of these substrates that overlap or were unique to each cell type. (B) Membrane topology of the putative BACE1
substrates. (C) Putative BACE1 substrates were divided into several functional categories based on known protein functions and gene ontology
classifications. (D) Sequence of APP, with peptides identified to be elevated by BACE1 expression indicated in red. The APP transmembrane sequence
is highlighted in yellow, and arrowheads indicate the b- (major and minor sites), a-, c-40 and c-42 secretase cleavage sites (from left to right). APP-770
amino acid numbering is indicated on the left.
doi:10.1371/journal.pone.0008477.g002
Figure 3. BACE1 shedding of GPI-linked and type II transmembrane proteins. Identified BACE1 substrates ephrin-A5 and GOLIM4 were
cloned, FLAG-tagged, and stably expressed in HEK cells that express BACE1 or empty vector as control. The left column shows Western blots of cell
lysates, and the right column shows blots of conditioned medium. Cells were treated with the b-secretase inhibitor C3 to confirm the necessity of
BACE1 activity for ectodomain shedding. (A) Ephrin-A5, a GPI-linked protein, was robustly expressed and produced two prominent bands, the lower
presumably representing the processed and mature GPI-linked form. BACE1 activity decreased the levels of full-length protein, and the shed product
was visible within the cellular lysate (left panel). Conditioned medium revealed one minor (ephrin-A5sa) and one major (ephrin-A5sb) band indicative
of shed ephrin-A5, the major band corresponding to the BACE1 cleavage product (right panel). (B) GOLIM4, a type II transmembrane protein, was
poorly expressed in cellular lysates (left panel), but accumulation of the shed ectodomain was found in conditioned medium of BACE1 expressing
cells (right panel).
doi:10.1371/journal.pone.0008477.g003
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accumulated APLP1 ectodomain that depended on b-secretase
activity (Figure 4D, right panel). These data highlight the
sensitivity of the methods employed in this study, as we were able
to detect BACE1-dependent processing of substrates expressed at
undetectable levels in cellular lysates.
By mass spectrometry, we have identified a number of proteins
involved in contact-dependent intercellular communication. Many
of these newly identified b-secretase substrates may conceivably
contribute to the observed BACE1 knockout phenotype based
upon their previously defined functions in the nervous system. We
chose to examine the processing of semaphorins as a representa-
tive type I substrate involved in intercellular communication. The
semaphorin family consists of eight classes of proteins that each
have distinct domains and are either membrane bound or
secreted. Different classes of semaphorins bind to unique
receptors, which include plexins and neuropilins, and receptor
binding induces signaling that regulates actin dynamics [48]. In
addition to regulating neuronal migration and synaptic plasticity,
semaphorins have also been found to be involved in the
development of other organ systems [49]. We chose to examine
the processing of semaphorin 4C (Sema4C), which is a type I
transmembrane protein and has been found to interact with post-
synaptic density proteins in the nervous system [50] and contribute
to myoblast differentiation [51].
We stably expressed Sema4C in HEK cells also expressing
either BACE1 or empty vector as a control. Probing for the N-
terminal FLAG tag, we detected strong expression of Sema4C in
cellular lysates, with levels of the full-length protein reduced by b-
secretase activity (Figure 5A, left panel). Examination of the
conditioned medium from these cells revealed a low level of
shedding of Sema4C, which was greatly enhanced by increasing b-
secretase activity (Figure 5A, right panel). In addition, we
examined processing of the membrane-bound C-terminal frag-
ment of Sema4C that is produced after ectodomain shedding by
appending an HA epitope tag to the C-terminus. Anticipating
Figure 4. BACE1 shedding of type I transmembrane proteins. Identified BACE1 substrates of type I topology were either cloned and stably
expressed or the endogenous protein was analyzed in HEK cells by Western blot. Cell lysates are shown in the left column, and conditioned medium
shown in the right column. (A) LRIG2 was expressed in cell lysates as several distinct bands, likely owing to differential glycosylation (left panel). LRIG2
shedding by BACE1 was observed in the conditioned medium (right panel). (B) LRIG3 was stably expressed, as shown in cell lysates (left panel). LRIG3
was shed by BACE1 into the conditioned medium (right panel). (C) Endogenous IGF2R was analyzed with an ectodomain directed antibody. b-
secretase activity produced a prominent decline in the full-length protein (left panel), and an increase in the shed ectodomain in the conditioned
medium (right panel). (D) Endogenous APLP1 was expressed at undetectable levels in the cell lysate (left panel; the asterisk denotes a background
band) but accumulated in the conditioned medium due to BACE1-mediated ectodomain shedding (right panel).
doi:10.1371/journal.pone.0008477.g004
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Sema4C CTF would be processed by c-secretase, we applied the
c-secretase inhibitor DAPT. In control cells, and to a greater
extent in BACE1 expressing cells, we found Sema4C CTF levels to
dramatically increase with DAPT inhibitor treatment, indicating
the processing of Sema4C by c-secretase (Figure 5B).
In addition to validating putative substrates, we also examined
several candidate non-substrates for changes in protein abundance
or aberrant shedding arising from BACE1 expression. These
proteins were not enriched in conditioned medium by BACE1
expression as determined by mass spectrometry and have
previously not been found to undergo b-secretase processing.
We examined endogenous levels of two well studied type I
transmembrane proteins not known to be shed: nicastrin (Nct) and
integrin b-1 (Itgb1). In both cases, BACE1 expression did not
change the levels of protein in the cellular lysates and did not
produce ectodomain shedding into the conditioned medium
(Figure 6A–B). Additionally, we used the same stable expression
model as was used for validating substrates to examine
angiotensin-converting enzyme (ACE), which is shed by metallo-
proteases but not known to be shed by b-secretase [52,53]. Lysates
from cells overexpressing ACE showed comparable abundance of
the full-length protein (Figure 6C, left panel). Shed ACE was
found in the conditioned medium, as expected, although levels
were found to be decreased by b-secretase activity (Figure 6C, right
panel). The reduction in ACE shedding is likely the consequence
of b-secretase cleavage of a metalloprotease contributing to ACE
cleavage (e.g. ADAM10 [Table 1] or a similar metalloprotease).
These results indicate that ACE is not a BACE1 substrate, but that
BACE1 may indirectly regulate the shedding of non-substrates
through the b-secretase processing of other ectodomain proteases.
By mass spectrometry, we found four unique peptides that
correspond to the BACE1 ectodomain that were elevated with
BACE1 expression (Table 1). Previous reports have identified
BACE1 shedding, with a metalloprotease being the responsible
enzyme [54]. To replicate this finding and establish whether
BACE1 could shed itself, we used an ectodomain directed
antibody to probe for soluble BACE1. In cellular lysates, we
observed robust BACE1 expression upon transfection, but
endogenous BACE1 was undetectable in HEK cells (Figure 6D,
left panel). In the conditioned medium, one major and one minor
immunoreactive band was detected. The minor band was
insensitive to b-secretase inhibition, but did decrease with
GM6001, a broad spectrum metalloprotease (a-secretase) inhibitor
(Figure 6D, right panel). The major band, however, was insensitive
to both metalloprotease and b-secretase inhibition, suggesting that
an additional protease contributes to BACE1 shedding, and that
BACE1 is unable to shed itself.
These results demonstrate that BACE1 is responsible for
shedding numerous substrates, but that not all type I membrane
Figure 5. Semaphorin 4C is processed by BACE1 and c-secretase. Semaphorin 4C was cloned with an N-terminal FLAG tag and a C-terminal
HA tag, and stably expressed in HEK cells overexpressing BACE1 or empty vector as control. (A) Cell lysates show a single prominent band for mature
Sema4C (left panel), which is shed by b-secretase activity into the medium (right panel). (B) Cells were treated with the c-secretase inhibitor DAPT and
cell lysates were probed for the presence of CTFs using the C-terminal HA epitope tag.
doi:10.1371/journal.pone.0008477.g005
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processing. Though a few BACE1 substrate cleavage sites have
been mapped [27,28,29] and other studies have examined BACE1
cleavage of peptide libraries (see Discussion for details), little
predictive information is available to aid in identifying putative
substrates a priori. Our analysis of the sequences of several
substrates reveals that all contain potential BACE1 cleavage sites
(Figure 7A, gray boxes), as predicted by in vitro studies and
comparison to known substrate cleavage sites (Figure 7A, black
boxes). However, proteins found not to be processed by BACE1
also contain similar potential cleavage sites (Figure 7B). Therefore,
BACE1 requires other permissive factors that are presently unclear
to initiate substrate cleavage.
Discussion
For its role in APP processing and Ab generation, BACE1 is a
central actor in the pathogenesis of Alzheimer’s disease, and b-
secretase inhibition has become a therapeutic goal. However,
relatively little is known about the normal functions of BACE1 and
how prolonged enzyme inhibition would affect the cellular
processes it regulates. In this study, we have used unbiased and
quantitative proteomic methods to identify proteins shed by
BACE1 in two human epithelial cell lines. We have added over 60
putative b-secretase substrates to the previously small list of known
BACE1 targets. The vast majority of the substrates have a type I
topology, though some type II and GPI-linked proteins can also be
cleaved.
To validate the proteomics findings, we either probed for
endogenously expressed proteins or stably transfected a tagged
cDNA encoding the putative substrate into a cell culture model.
We examined putative substrates of type I, type II or GPI-linked
topology identified by our screen, and in every case, the identified
substrate was indeed confirmed to be processed by b-secretase. In
addition to ectodomain shedding, the levels of the membrane-
bound full-length protein were typically decreased with b-secretase
activity, as expected. We validated both substrates of high
confidence, in which over 100 peptides had been identified by
mass spectrometry, and low confidence, in which as little as one
peptide was identified. These results suggest that the remaining
putative b-secretase substrates emerging from our screen are
indeed subject to BACE1 cleavage, and future investigation will
shed light on the biological significance of their processing.
Previously, we used similar proteomic methods to identify novel
c-secretase substrates [22]. In comparison to the former study, we
have identified far more putative b-secretase substrates, and the
likely reasons lie both in the less complex subcellular fractionation
(secreted proteins versus membrane-bound proteins) used here and
the larger sizes of the proteins subjected to analysis (ectodomains
versus CTFs, thus offering more peptides for detection). The
identification of APLP1, which is expressed at very low levels in
the epithelial cells we tested, provides a clear example of the
sensitivity of these methods. Considering that the large majority of
putative b-secretase substrates are type I transmembrane proteins,
it is highly likely that the residual membrane-anchored CTFs
Figure 6. Single pass membrane proteins unaltered by b-secretase activity. Endogenous membrane proteins nicastrin (Nct, A) and Itgb1 (B)
were found not to be shed by BACE1 or another secretase. ACE (C) and BACE1 (D) were both shed by metalloproteases, but not affected by b-
secretase activity. Left panels are from cell lysates, and right panels are from conditioned medium.
doi:10.1371/journal.pone.0008477.g006
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to generate secreted Ab-like peptides and a soluble intracellular
domain. If true, our findings would substantially expand the list of
known c-secretase substrates.
In addition to the novel b-secretase substrates it identified, our
unbiased proteomic method also revealed other proteins that are
elevated by BACE1 overexpression but are unlikely to be directly
processed by the protease. We found that the majority of these
proteins are soluble lysosomal enzymes. The identification of
IGF2R/M6PR ectodomain shedding by BACE1 provides a
plausible mechanistic explanation for the presence of the
extracellular lysosomal enzymes (see Table S2). This cellular
phenotype, in which lysosomal proteins accumulate in the
extracellular space, is mechanistically similar to the autosomal
recessive human disorder, I-cell disease (mucolipidosis II), in which
mutations in N-acetylglucosamine 1-phosphotransferase disrupt
normal mannose-6-phosphate labeling of lysosomal proteins,
preventing their receptor binding and leading to their secretion.
In the analogous case of cellular BACE1 overexpression, elevated
IGF2R shedding reduces the number of intact receptors able to
mediate lysosomal transport and/or promotes the co-shedding of
the IGF2R ectodomain with bound lysosomal proteins, thus
increasing lysosomal protein secretion. Only four other non-
membrane bound proteins were found to be elevated in
conditioned medium due to BACE1 overexpression in our screen,
and this may well have occurred through similar, but less clear,
mechanisms of mistrafficking or co-shedding with an actual
substrate.
The mechanism by which BACE1 selects its substrates has
remained unclear despite over a decade of examination. BACE1 is
related to other aspartyl proteases, including renin, cathepsin D
and pepsin, and shows ,50% sequence identity with the
homologous BACE2 protein. There is a high degree of BACE1
sequence conservation among mammalian species [18]. However,
except for BACE2, there is little similarity between BACE1 and
other aspartyl proteases in terms of substrate profiles and inhibitor
sensitivity. In vitro experiments with peptide libraries have shown
BACE1 to prefer hydrophobic residues at P1 and P3, to accept
polar residues at positions P2’ and P1, and to display very low
catalytic efficiency, even towards optimized peptide substrates
[17]. Molecular modeling studies have identified a hydrophobic
pocket that may bind to the P1 hydrophobic residue, and Arg296
also may form a salt bridge with a charged P1’ residue, which may
help explain BACE1’s unique substrate preferences [18].
Another approach to determining substrate specificity has been
to make modified APP constructs and monitor alterations in b-
secretase processing [16]. These studies showed that, at least for
APP, cleavage requires a membrane anchor and most mutations
around the scissile bond decrease processing. Almost the entire
APP ectodomain can be deleted without changing cleavage
efficiency, and the cleavage site can tolerate shifts of at least five
amino acids closer to the membrane. In other studies, introduction
of the seven amino acids flanking the APP cleavage site into the
juxtamembrane domain of a non-substrate permitted b-secretase
cleavage of the hybrid protein [26].
These results all suggest that BACE1 has relatively loose
sequence specificity and that regions outside the cleavage site may
not play a critical role in substrate selection. However, in
candidate-based approaches, the enzyme has been unable to
process many type I transmembrane proteins known to be shed by
the more promiscuous a-secretases (metalloproteases that include
ADAMs and MMPs) [27,28]. Analysis of the primary sequences of
BACE1 substrates reveals potential cleavage sites, but similar
sequences are also found in non-substrates (Figure 7), indicating
that other factors are required for b-secretase processing. These
factors may include accessibility of the cleavage site, sequestration
of the substrate through incorporation into larger complexes,
conformational change after ligand binding, and subcellular
localization. Our identification of many new putative substrates
should enable experiments to understand better the mechanisms
underlying BACE1 substrate selection and what role b-secretase
processing plays in modulating a particular substrate’s function.
Taken together, the findings presented here should enhance our
understanding of the normal cellular functions to which BACE1
contributes and improve our search for potential adverse events
when considering this protease as a therapeutic target.
Figure 7. Alignment of b-secretase substrates and putative cleavage sites. The primary amino acid sequence of BACE1 substrates (A) and
non-substrates (B) are shown. The first ten amino acids of the transmembrane domain are included, if present. Known cleavage sites are indicated
with a black box and arrowhead, and potential cleavage sites are in gray. All sequences are human, except ST6Gal I, whose cleavage site was
determined in rat. Sequence from type II proteins is listed from C- to N-terminal to maintain membrane orientation.
doi:10.1371/journal.pone.0008477.g007
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Cell Culture and Treatments
The epithelial cell lines HeLa (ATCC) and human embryonic
kidney (HEK) 293-FT (Invitrogen) were grown in Dulbecco’s
modified Eagle’s medium containing 10% FBS, 2 mM L-
glutamine, 100 mg/ml penicillin, and 100 mg/ml streptomycin.
Transfections were performed with Fugene 6 (Roche Applied
Sciences). Stable cell lines were generated by transduction with
lentivirus containing the cDNAs of interest, as previously described
[6]. Cells were treated with the b-secretase inhibitor C3 (3–6 mM,
BACE inhibitor IV), the metalloprotease inhibitor GM6001
(10–20 mM) or the c-secretase inhibitor DAPT (10 mM) for 18 to
20 hr in Opti-MEM I (Invitrogen). All drugs were purchased from
Calbiochem.
SILAC and LC-MS/MS
HEK and HeLa cell lines expressing either human BACE1 or an
empty vector control were propagated for six doublings in DMEM
lacking L-lysine and L-arginine (Invitrogen), and supplemented with
10% dialyzed fetal bovine serum (FBS) (Calbiochem), antibiotics,
and either
12C
14N arginine plus
12C
14N lysine (‘‘light’’) or
13C
15N
arginine plus
13C
15N lysine (‘‘heavy’’) (Cambridge Isotope Labora-
tories). Cells overexpressing BACE1 were grown under heavy
labeling conditions, and control cells under light. Once labeled, the
confluent cells were extensively washed and then treated with
serum-free medium containing 20 mM GM6001 for 20 hr to inhibit
a-secretases. Conditioned medium from this treatment was
collected, floating cellular debris removed by centrifugation, and a
small aliquot was analyzed by Western blotting.
Equal volumes of conditioned medium from BACE1 overex-
pressing and control cells were combined and concentrated
approximately 200-fold using Centricon filter devices with a
3 kDa cutoff (Millipore). Approximately one hundred micrograms
of protein from the concentrated media were run on an 4–12%
Bis-Tris SDS-PAGE gel, stained with Coomassie Blue, divided
into ten horizontal gel slices by molecular weight, and subject to
in-gel digestion with trypsin (see Figure S1 for a schematic).
Liquid chromatography tandem mass spectrometry (LC-MS/
MS) was performed using an LTQ Orbitrap hybrid mass
spectrometer (Thermo Scientific). Resulting MS/MS spectra were
matched to a composite target-decoy [55] human sequence
database [56], using both SEQUEST and Mascot search engines.
An in-house algorithm was used to select confident peptide
identifications with an estimated false discovery rate less than 1%.
Confident peptide identifications were then subjected to Vista, an
automated software suite which measures the relative abundance of
light and heavy isotopic peptide pairs [57,58]. Proteins containing
peptides with at least 65% of the total (light plus heavy) signal
derived from the BACE1 (heavy) condition were considered as
putativesubstrates.Thisthresholdvalueisequivalenttoa1.857-fold
(0.65/0.35) increase in peptide abundance.
Cloning
Full-length cDNAs were obtained from the NIH Mammalian
Gene Collection unless otherwise described. The LRIG2, LRIG3
and GOLIM4 cDNA were from mouse, and all other cDNAs were
human in origin. Type I transmembrane and GPI-linked proteins
were N-terminally tagged with the FLAG epitope (DYKDDDDK)
by inserting the sequence encoding FLAG into primers and using
an overlapping PCR method to generate the full-length tagged
construct as previously described [22]. Epitope tags were inserted
at least 5 amino acids downstream of the predicted signal peptide
cleavage site. Type II transmembrane proteins were C-terminally
tagged by inserting the FLAG sequence upstream of the stop
codon, thus adding the epitope tag to the ectodomain. An extreme
C-terminal HA tag (YPYDVPDYA) was also added to semaphorin
4C by identical methods. BACE1 was C-terminally myc-tagged.
All expression constructs were verified by DNA sequencing.
Immunoblotting
Cells were lysed in 50 mM Tris-HCl (pH 7.4), 1% NP-40,
protease inhibitor cocktail (Roche Applied Sciences), 2 mM 1,10-
phenanthroline and 5 mM EDTA. Lysates were centrifuged at
1,000 g for 10 min to remove nuclei. Protein concentrations were
determined using a bicinchoninic acid-based assay (Pierce
Biotechnology). Conditioned media were collected, cellular debris
removed by centrifugation, and 500 ml of each medium was
concentrated using a Microcon filter device (Millipore) with a
membrane cutoff of 30 kDa. Samples were then subjected to SDS-
PAGE and Western blotting. APP was detected using the
polyclonal antibody C9 (1:1,000) [53], CT20 (1:1,000, Calbio-
chem), or the ectodomain directed antibody 22C11 (1:1,000,
Chemicon); nicastrin with anti-nicastrin (1:1,000, BD Biosciences);
IGF2R with HPA011332 (1:1,000, Sigma); integrin beta-1 with
4706 (1:1,000, Cell Signaling); APLP1 with 1NT (1:1,000) [46];
BACE1 with Z-183 (1:1,000, Santa Cruz Biotechnology, Inc.) or
anti-myc 9E10 (1:1,000; Santa Cruz Biotechnology, Inc.); ACE
with H-170 (1:1,000, Santa Cruz Biotechnology, Inc); HA tag with
3F10 (1:1,000, Roche Applied Sciences); and FLAG tag with M2
(1:1,000, Sigma). Western blots were probed with anti-mouse,
anti-rabbit or anti-rat secondary antibodies (1:10,000, Rockland
Immunochemicals) and detected using the Odyssey infrared
imaging system (LI-COR Biosciences). Immunoblots shown are
representative of at least three experiments. Immunoreactive
proteins were quantified using Odyssey Software v1.2, and the
data were analyzed using a one-way analysis of variance with
Tukey post-hoc comparison or a two-tailed Student t-test, where
appropriate. Calculated comparisons of p , 0.05 were considered
significant. All reported values represent the means 6 standard
error of the mean (SEM).
Supporting Information
Table S1 Expanded information on putative b-secretase substrates.
Found at: doi:10.1371/journal.pone.0008477.s001 (0.05 MB
XLS)
Table S2 Putative non-substrate proteins elevated with BACE1
expression.
Found at: doi:10.1371/journal.pone.0008477.s002 (0.03 MB
XLS)
Figure S1 SILAC and LC-MS/MS approach to identifying
proteins differentially shed between BACE1 and control cell lines.
BACE1 and control cells were grown in the presence of heavy
(BACE1) or light (control) lysine and arginine. Once labeled, the
cells were incubated in serum-free medium, and the conditioned
medium was collected. (A) APPs levels were evaluated in the
resulting medium (the HEK line is shown), and equal volumes
of the collected medium from BACE1 and control cells were
combined. (B) The combined media were concentrated 200-fold,
and approximately 100 mg of protein was separated on an SDS-
PAGE gel. The gel was cut into 10 horizontal regions of
approximately equal protein abundance. (C) Proteins were
trypsinized and subject to LC-MS/MS analysis. Putative BACE1
substrates elevated in conditioned medium would be expected to
show an increased relative abundance of peptides, which being
labeled with heavy amino acids would have a predictably
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graphical example of data from the proteomics screen is shown
in D and E. (D) MS spectra of the APP peptide LEVPTDG-
NAGLLAEPQIAMFCGR, with the red vertical line indicating
the beginning of the light spectra and the blue line indicating the
heavy (BACE1) spectra. (E) Relative abundance of APP peptides
in heavy (BACE1, blue) and light (control, red) conditions. The
area underneath each of these curves was used to calculate the
ratio of BACE1 peptides to total peptides.
Found at: doi:10.1371/journal.pone.0008477.s003 (1.00 MB TIF)
Figure S2 Mapping of identified peptides to putative b-secretase
substrates.
Found at: doi:10.1371/journal.pone.0008477.s004 (0.29 MB
PDF)
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